Oxiracetam

Cognitive impairment is a major public health challenge facing the aging society. Oxiracetam, a piracetam-type γ-aminobutyric acid derivative, promotes the synthesis of adenosine triphosphate and acetylcholine in the brain, enhances the metabolic function of nerve cells, and improves cerebral energy metabolism and neuroplasticity. It is mainly used clinically for memory and intellectual impairment caused by mild to moderate vascular dementia, senile dementia and brain trauma, etc. It has definite clinical value in improving patients' cognitive function and enhancing their ability of daily living, and is a commonly used nootropic drug in the field of central nervous system.

At present, the global market size of oxiracetam is about 1.8 billion US dollars, with a compound annual growth rate maintained at around 6.2%, among which the Chinese market accounts for more than 45%, making it the largest consumer market in the world. The domestic market presents a competitive landscape dominated by generic drugs, and there are more than 30 approved preparation manufacturers. As the fourth batch of national centralized drug procurement included oxiracetam injection into the procurement scope, the average price reduction of winning bids exceeded 70%, the demand for cost control of downstream preparation enterprises has increased significantly, and the stability and cost-effectiveness of the upstream API supply chain have become the core competitive factors in the market.

The original research enterprise of oxiracetam is SmithKline Beecham Italy, with the original brand name "Neuromet", and the core compound patent expired globally in 2003. The main dosage forms approved by the original research include capsules (800mg) and injections (1g/5ml), both of which have been included in the China Listed Drugs Catalog as reference preparations. Up to now, more than 30 enterprises have had their oxiracetam APIs registered in Status A on the API Registration Platform of China CDE. The domestically approved oxiracetam preparations cover capsules, tablets, injections and other dosage forms, with high clinical accessibility. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for oxiracetam API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide reliable reference standard support for API and preparation enterprises in the links of quality research, stability study, registration and declaration, etc.